After screening several compounds that target oncogenic pathways known to upregulate MCL-1 [10, 26–29], we identified that AZD8055, a mTORC1/2 ATP-competitive inhibitor, and everolimus, a selective mTOR1 inhibitor, can selectively suppress MCL-1 expression in SCLC cells but not in normal cells. The gene discussed is MCL1; the disease is small cell lung carcinoma.